A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer

Summary

This is a multicenter, open-label, phase II study to explore the efficacy, safety/tolerability and pharmacokinetics (PK) of GFH375 in in Patients with Previously Treated KRAS G12D Mutant Metastatic Pancreatic Cancer.

Timeline

Start

2025-08

Primary completion

2027-08

Completion

2028-08

Outcome

Outcome not reported

Stopped (Business): “Adjustment of Product Development Strategy”

Drugs

Indications